- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05216133
Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BADBURN)
AERODIGESTIVE DISEASE IN THE WORLD TRADE CENTER EXPOSED FDNY COHORT: a Single Center Observational Study of Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BADBURN)
A majority of Fire Department of New York (FDNY) World Trade Center (WTC) exposed rescue and recovery workers developed gastroesophageal reflux disease (GERD), a risk factor for Barrett's Esophagus (BE) and subsequent esophageal cancer. There is diminished health-related quality of life and productivity associated with aerodigestive diseases such as GERD and BE.
This proposal will leverage the longitudinally phenotyped WTC exposed cohort, validate biomarkers of WTC-aerodigestive disease, and develop novel, noninvasive disease phenotyping of premalignant diseases such as BE, and identify potential targeted therapeutics to improve care.
Study Overview
Status
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Sanjiti Podury, MD
- Phone Number: 646-501-6783
- Email: Sanjiti.Podury@nyulangone.org
Study Contact Backup
- Name: Urooj Javed, MD
- Email: Urooj.Javed@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Clinical & Translational Science Institute Clinical Research Center (CTSI CRC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 37-90
- FDNY rescue and recovery worker.
- Male*
- Documented WTC exposure.
- Consented/Enrolled in the FDNY WTC Health Program
- Subjects are willing and able to consent for themselves to study enrollment
- Subjects are willing and able to participate in study procedures
- Are able to perform their activities of daily living independently
- Are either light duty or retired FDNY Firefighters
- Spirometry available within the last 24 months, and at a post-9/11 visit.
- Have means to accommodate transportation to/from in-person visit Are able to attend a single visit at the CTSI (462 1st Avenue, C & D 4th Floor)
- Pre-9/11 spirometry with FEV1%predicted ≥LLN and if not available 1st -post 9/11 spirometry with an FEV1 >80% predicted.
- Exposure at the WTC-site within 2 weeks of the 9/11/2001
- Entered WTC-HP before the site closure on 7/24/2002.
- Serum from their first post 9/11 WTC-HP visit is available in the FDNY WTC biorepository and may be assayed
- Are not currently being treated for malignancy
- Subjects will either need to be defined as having WTC-AHR, WTC-GERD, WTC-BE or be designated controls as per the following additional inclusion criteria are specific to the WTC-aerodigestive disease that the subjects have
- AHR--A positive methacholine (PC20<16) and/or positive bronchodilator response (ATS/ERS guidelines: improvement of FEV1 by 12% and at least 200mL) at least once post-9/11.[95, 96]No recorded positive AHR testing prior to 9/11
GERD Inclusion Criteria
- Erosive esophagitis LA grade C or D (as described on endoscopy), OR
- Stricture or Barrett's esophagus on endoscopy, OR
- Esophageal acid exposure time >6% on a pH or pH impedance study
19. BE Inclusion Criteria
- Columnar epithelium lining ≥1 cm of the distal esophagus. AND
- Histologic examination of biopsy specimens from that columnar epithelium must reveal intestinal metaplasia characterized with goblet cells.
Exclusion Criteria:
- Unwilling to complete an informed consent.
- Not enrolled in the WTC-HP
- Do not meet eligibility criteria for AIM 1 or did not have serum available in the biorepository from the first post 9/11 WTC-HP visit.
- Have pre-existing and documented conditions or concurrent diagnoses, including (and not necessarily limited to) active cancer, severe heart disease, significant cognitive impairment, eating disorders, significant psychiatric illness, end-stage COPD, severe pulmonary hypertension, or organ transplant.
- High dose steroid (>20mg prednisone or equivalent) or other hormonal treatments/chemotherapy use in the last month, including testosterone supplementation.
- Life-expectancy < 6 months
- Female*
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score on St. George's Respiratory Questionnaire (SGRQ-C)
Time Frame: up to Day 365
|
SGRQ-C is designed to assess how one's breathing is troubling a participant and how it affects one's life.
The questionnaire consists of 14 questions.
The total score range is 0-54; the higher the score, the worse the chest trouble.
|
up to Day 365
|
Levels of salivary pepsin
Time Frame: up to Day 365
|
Saliva will be analyzed using the Peptest.
The value of >/= 16 ng/mL indicates a positive salivary pepsin.
|
up to Day 365
|
pH Levels from Exhaled Breath Condensate (EBC)
Time Frame: up to Day 365
|
EBC pH assay will be performed
|
up to Day 365
|
Histamine Concentration from Exhaled Breath Condensate (EBC)
Time Frame: up to Day 365
|
Histamine concentration will be measured with an enzymatic immunoassay
|
up to Day 365
|
Score on Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) Questionnaire
Time Frame: up to Day 365
|
PAGI-QOL asks about how some of the gastrointestinal problems one may be experiencing (such as pain, discomfort, or other problems) may have affected one's overall quality of life and well-being in the past 2 weeks.
PAGI-QOL consists of 30 questions, each scored from 0 (none of the time) to 5 (all of the time).
The total score range is 0-150; the higher the score, the less the quality of life and well-being.
|
up to Day 365
|
Score on Patient Assessment of Upper Gastrointestinal Disorders-Symptoms (PAGI-SYM) Questionnaire
Time Frame: up to Day 365
|
PAGI-SYM asks about the severity of symptoms one may have related one's gastrointestinal problem.
The questionnaire consists of 20 symptoms, and each symptom is scored from 0 (none) to 5 (very severe).
The total score range is 0-100; the higher the score, the more severe the symptoms.
|
up to Day 365
|
36-Item Short Form Survey Instrument (SF-36)
Time Frame: up to Day 365
|
SF-36 captures mental health, general health perception, emotional, and social role functioning.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
|
up to Day 365
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anna Nolan, MD, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-00679
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux Disease
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
King Chulalongkorn Memorial HospitalCompleted
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
PfizerTerminatedGastroesophageal Reflux DiseaseBrazil, Germany, Korea, Republic of, Belgium, Spain, Slovakia, France
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux Disease (GERD) | RefluxUnited States, Canada